Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Replidyne restructures, seeks alternatives

RDYN restructured and reduced headcount to 54 from 81. The company also said it will seek strategic alternatives, including

Read the full 196 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE